NCT04830020View on ClinicalTrials.gov

Use of Inhaled High-molecular Weight Hyaluronan in Patients With Severe COVID19: Feasibility and Outcomes

PHASE2CompletedINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

February 26, 2021

Primary Completion Date

June 30, 2021

Study Completion Date

September 30, 2021

Conditions

Covid19

Interventions

DRUG

HMW-HA

Aerolized administration b.i.d.

Trial Locations (1)

00128

Università Campus Biomedico di Roma, Roma

All Listed Sponsors

collaborator

National Institute of Environmental Health Sciences (NIEHS)

NIH

lead

Campus Bio-Medico University

OTHER

NCT04830020 - Use of Inhaled High-molecular Weight Hyaluronan in Patients With Severe COVID19: Feasibility and Outcomes | Biotech Hunter | Biotech Hunter